Does the media prefer HIMS or VRDN?

In the previous week, Hims & Hers Health had 21 more articles in the media than Viridian Therapeutics. MarketBeat recorded 25 mentions for Hims & Hers Health and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.37 beat Hims & Hers Health's score of 0.55 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRDN or PACS?

In the previous week, PACS Group had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for PACS Group and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.37 beat PACS Group's score of -0.05 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CAI or VRDN?

In the previous week, Viridian Therapeutics had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 4 mentions for Viridian Therapeutics and 3 mentions for Caris Life Sciences. Viridian Therapeutics' average media sentiment score of 1.37 beat Caris Life Sciences' score of 0.51 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLLN or VRDN?

In the previous week, Billiontoone had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Billiontoone and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.37 beat Billiontoone's score of -0.18 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$17.28 -0.35 (-1.99%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$17.45 +0.17 (+1.01%)

As of 05:10 AM Eastern

Compare

VRDN vs. HIMS, PACS, CAI, BLLN, and SHC

Should you buy Viridian Therapeutics stock or one of its competitors? MarketBeat compares Viridian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viridian Therapeutics include Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), Billiontoone (BLLN), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does Viridian Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Hims & Hers Health had 21 more articles in the media than Viridian Therapeutics. MarketBeat recorded 25 mentions for Hims & Hers Health and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.37 beat Hims & Hers Health's score of 0.55 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than Viridian Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.37B	3.22	$128.37M	-$0.09	N/A
Viridian Therapeutics	$70.92M	25.12	-$342.60M	-$3.32	N/A

Hims & Hers Health has a net margin of -0.56% compared to Viridian Therapeutics' net margin of -490.31%. Hims & Hers Health's return on equity of 6.10% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

63.5% of Hims & Hers Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hims & Hers Health presently has a consensus target price of $29.37, indicating a potential downside of 11.01%. Viridian Therapeutics has a consensus target price of $36.14, indicating a potential upside of 109.16%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Hims & Hers Health beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to PACS Group?

Viridian Therapeutics (NASDAQ:VRDN) and PACS Group (NYSE:PACS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

PACS Group has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.92M	25.12	-$342.60M	-$3.32	N/A
PACS Group	$5.29B	1.12	$191.54M	$1.56	23.90

Viridian Therapeutics presently has a consensus price target of $36.14, indicating a potential upside of 109.16%. PACS Group has a consensus price target of $48.00, indicating a potential upside of 28.72%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

PACS Group has a net margin of 4.49% compared to Viridian Therapeutics' net margin of -490.31%. PACS Group's return on equity of 26.47% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
PACS Group	4.49%	26.47%	4.36%

In the previous week, PACS Group had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for PACS Group and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.37 beat PACS Group's score of -0.05 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PACS Group beats Viridian Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Caris Life Sciences currently has a consensus target price of $27.56, indicating a potential upside of 56.57%. Viridian Therapeutics has a consensus target price of $36.14, indicating a potential upside of 109.16%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Viridian Therapeutics had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 4 mentions for Viridian Therapeutics and 3 mentions for Caris Life Sciences. Viridian Therapeutics' average media sentiment score of 1.37 beat Caris Life Sciences' score of 0.51 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	6.13	-$68.09M	-$7.61	N/A
Viridian Therapeutics	$70.92M	25.12	-$342.60M	-$3.32	N/A

Caris Life Sciences has a net margin of 3.75% compared to Viridian Therapeutics' net margin of -490.31%. Caris Life Sciences' return on equity of 98.28% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Summary

Viridian Therapeutics beats Caris Life Sciences on 7 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Billiontoone currently has a consensus target price of $125.29, suggesting a potential upside of 20.14%. Viridian Therapeutics has a consensus target price of $36.14, suggesting a potential upside of 109.16%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Billiontoone has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	15.72	$7.45M	$0.55	189.60
Viridian Therapeutics	$70.92M	25.12	-$342.60M	-$3.32	N/A

In the previous week, Billiontoone had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Billiontoone and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.37 beat Billiontoone's score of -0.18 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Billiontoone has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Billiontoone's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Summary

Billiontoone beats Viridian Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Sotera Health?

Viridian Therapeutics (NASDAQ:VRDN) and Sotera Health (NASDAQ:SHC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Viridian Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Sotera Health has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

In the previous week, Viridian Therapeutics had 4 more articles in the media than Sotera Health. MarketBeat recorded 4 mentions for Viridian Therapeutics and 0 mentions for Sotera Health. Viridian Therapeutics' average media sentiment score of 1.37 beat Sotera Health's score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Viridian Therapeutics	Positive
Sotera Health	Neutral

Sotera Health has a net margin of 9.91% compared to Viridian Therapeutics' net margin of -490.31%. Sotera Health's return on equity of 39.73% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Sotera Health	9.91%	39.73%	7.05%

91.0% of Sotera Health shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 15.4% of Sotera Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sotera Health has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.92M	25.12	-$342.60M	-$3.32	N/A
Sotera Health	$1.19B	3.80	$77.94M	$0.41	38.63

Viridian Therapeutics presently has a consensus price target of $36.14, indicating a potential upside of 109.16%. Sotera Health has a consensus price target of $20.29, indicating a potential upside of 28.07%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Sotera Health beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-5.20	19.75	24.66	23.99
Price / Sales	25.12	330.65	527.00	106.82
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.80	8.29	10.75	6.50
Net Income	-$342.60M	$23.85M	$3.56B	$336.88M
7 Day Performance	3.41%	2.87%	1.00%	-0.14%
1 Month Performance	0.23%	2.19%	0.43%	0.77%
1 Year Performance	17.87%	55.48%	29.69%	28.49%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	3.9797 of 5 stars	$17.28 -2.0%	$36.14 +109.2%	+17.5%	$1.82B	$70.92M	N/A	50	Positive News
HIMS Hims & Hers Health	3.0864 of 5 stars	$30.10 +12.2%	$28.70 -4.6%	-21.6%	$6.21B	$2.35B	N/A	2,442	Trending News Insider Trade Gap Down
PACS PACS Group	3.7824 of 5 stars	$36.23 -0.2%	$48.00 +32.5%	+192.0%	$5.74B	$5.29B	23.22	47,455	News Coverage Insider Trade Gap Up
CAI Caris Life Sciences	4.4288 of 5 stars	$18.18 +1.2%	$27.56 +51.6%	N/A	$5.08B	$812.03M	N/A	1,846	Gap Up
BLLN Billiontoone	3.5994 of 5 stars	$103.95 +2.8%	$125.29 +20.5%	N/A	$4.65B	$305.11M	189.00	620

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. HIMS, PACS, CAI, BLLN, and SHC

How does Viridian Therapeutics compare to Hims & Hers Health?

Summary

How does Viridian Therapeutics compare to PACS Group?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Summary

How does Viridian Therapeutics compare to Sotera Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. HIMS, PACS, CAI, BLLN, and SHC

How does Viridian Therapeutics compare to Hims & Hers Health?

Does the media prefer HIMS or VRDN?

Which has more risk & volatility, HIMS or VRDN?

Which has preferable valuation and earnings, HIMS or VRDN?

Is HIMS or VRDN more profitable?

Do insiders and institutionals believe in HIMS or VRDN?

Do analysts prefer HIMS or VRDN?

Summary

How does Viridian Therapeutics compare to PACS Group?

Which has stronger earnings & valuation, VRDN or PACS?

Do analysts prefer VRDN or PACS?

Is VRDN or PACS more profitable?

Does the media favor VRDN or PACS?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Do analysts rate CAI or VRDN?

Does the media refer more to CAI or VRDN?

Which has stronger valuation & earnings, CAI or VRDN?

Is CAI or VRDN more profitable?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Do analysts recommend BLLN or VRDN?

Which has better earnings and valuation, BLLN or VRDN?

Does the media prefer BLLN or VRDN?

Is BLLN or VRDN more profitable?

Summary

How does Viridian Therapeutics compare to Sotera Health?

Which has more volatility and risk, VRDN or SHC?

Does the media refer more to VRDN or SHC?

Is VRDN or SHC more profitable?

Do institutionals and insiders believe in VRDN or SHC?

Which has better valuation & earnings, VRDN or SHC?

Do analysts rate VRDN or SHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools